Figure 4 from Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells

PARP7i and AHRa response biomarker is associated with response to ICI therapy. A, Heatmap showing Spearman correlation coefficients between the two biomarker genes and immune cell types in TCGA-BRCA and TCGA-PRAD patient data. B, ROC curve showing the performance of the two-gene classifier in distinguishing response to the anti–PD-1 antibody, nivolumab, in kidney cancer. The AUC represents the probability that a randomly selected anti–PD-1–responsive patient will have a higher biomarker score than a randomly selected nonresponsive patient. C, Kaplan–Meier survival curves showing the OS of patients with cancer receiving anti–PD-L1 (left) or anti–CTLA-4 treatment (right). Patients were stratified into “high” and “low” groups based on the median value of the PARP7i and AHRa response biomarker scores. Patients with biomarker scores above than median were classified as “high” and those below as “low.” HR and P values are included on each plot. The numbers of surviving patients at each timepoint in the “high” and “low” groups are indicated below each plot.